DeepMed Research

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

BTZ-043

Generic Name: BTZ-043

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₆F_₃N_₃O_₅S

CAS Number: 1161233-85-7

Unique Ingredient Identifier: G55ZH52P57

Overview

No overview information available.

Background

No background information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB

Phase 2

Recruiting

Posted: 2023/11/02

Sponsor:University College, ...

BTZ-043 Dose Evaluation in Combination and Selection

Phase 2

Recruiting

Posted: 2023/07/03

Sponsor:

Michael Hoelscher

PanACEA - STEP2C -01

Phase 2

Recruiting

Posted: 2023/04/11

Sponsor:

Michael Hoelscher

Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin Susceptible Pulmonary Tuberculosis

Phase 2

Recruiting

Posted: 2022/05/19

Sponsor:GlaxoSmithKline

BTZ-043 - Multiple Ascending Dose (MAD) to Evaluate Safety, Tolerability and Early Bactericidal Activity (EBA)

Phase 1

Completed

Posted: 2019/08/02

Sponsor:

Michael Hoelscher

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

BTZ-043 Shows Promising Efficacy in Tuberculosis Treatment by Targeting Necrotic Granulomas

4 months ago

The clinical-stage drug BTZ-043 demonstrates significant antimycobacterial activity in tuberculosis (TB) treatment, effectively reducing bacterial load in murine models. Its ability to penetrate and accumulate in necrotic granulomas, a challenging aspect of TB therapy, highlights its potential for improving treatment outcomes and preventing drug resistance.

Breakthrough in Tuberculosis Treatment: New Antibiotic BTZ-043 Shows Promising Results

4 months ago

A recent study published in The Lancet Microbe highlights the potential of a new antibiotic, BTZ-043, in combating tuberculosis (TB), a leading infectious disease worldwide. Developed by a European-African consortium, BTZ-043 has shown antibacterial efficacy and tolerability in clinical trials, offering hope against antibiotic-resistant TB strains.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy